Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study)

International Journal of Antimicrobial Agents

Volumn 33, Issue 1, 2009, Pages 52-57

  Jacobs, Enno ^a   Dalhoff, Axel ^b   Korfmann, Gisela ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c BAYER AG   (Germany)

Author keywords

ESBL; H. influenzae; K. pneumoniae; Levofloxacin; M. catarrhalis; Moxifloxacin; S. aureus; S. pneumoniae; Susceptibility

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CLARITHROMYCIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM; FEMALE; GERMANY; HAEMOPHILUS INFLUENZAE; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA; DRUG RESISTANCE, BACTERIAL; FEMALE; GERMANY; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MORAXELLA (BRANHAMELLA) CATARRHALIS; PREVALENCE; QUINOLINES; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 59349090109     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.07.017     Document Type: Article

References (25)

1. Abraham E.P., and Chain E. An enzyme from bacteria able to destroy penicillin. Nature 146 (1940) 837
2. Domagk G., and Hegeler C. Chemotherapie bakterieller Infektionen. In: Lendle L., and Schoen R. (Eds). Beiträge zur Arzneimitteltherapie, Band 1 (1940), Verlag von Hirzel, Leipzig, Germany 1-183
3. Cantón R., Loza E., Morosini I., and Baquero F. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J Antimicrob Chemother 50 Suppl. S1 (2002) 9-24
4. Felmingham D., Reinert R.R., Hirakata Y., and Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide telithromycin. J Antimicrob Chemother 50 Suppl. S1 (2002) 25-37
5. Farrell D.J., Morrissey D., Bakker S., and Felmingham D. Molecular characterisation of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 50 Suppl. S1 (2002) 39-47
6. Morrissey I., Farrell D.J., Bakker S., Enright M.C., and Felmingham D. Molecular characterisation of fluoroquinolone-resistant Streptococcus pneumoniae PROTEKT 2000 isolates from Hong Kong. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 16-19 December 2001, Chicago, IL (2001), American Society for Microbiology, Washington, DC [Abstract 703]
7. Deutsches Institut für Normug e.V. (DIN). Medizinische Mikrobiologie - Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika - Teil 4: Bewertungsstufen für die minimale Hemmkonzentration - MHK-Grenzwerte von antibakteriellen Wirkstoffen. DIN 58940-4; August 2005. Berlin, Germany: Beuth Verlag GmbH. http://www.din.de/cmd?level=tpl-home&contextid=din [accessed 3 July 2008].
8. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints. http://www.srga.org/eucastwt/MICTAB [accessed 3 July 2008].
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Tenth informational supplement (aerobic dilution) (2000), NCCLS, Villanova, PA
10. Steward C.D., Rasheed J.K., Hubert S.K., et al. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum β-lactamase detection methods. J Clin Microbiol 39 (2001) 2864-2872
11. Höffken G., Lorenz J., Kern W., et al. Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen tiefen Atemwegsinfektionen (akute Bronchitis, akute Exacerbation einer chronischen Bronchitis Influenza und andere respiratorische Virusinfektionen) sowie ambulant erworbener Pneumonie. Chemother J 14 (2005) 97-155
12. Felmingham D., and Grüneberg R.N. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project. J Antimicrob Chemother 38 Suppl. A (1996) 1-57
13. White L, Reeves D.S., editors. PROTEKT: an innovative surveillance programme for RTI pathogens. J Antimicrob Chemother 2002;50(Suppl. S1):1-70.
14. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvallez M., and Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 32 Suppl. 2 (2001) S81-93
15. Felmingham D., White A.R., Jacobs M.R., et al. The Alexander Project: the benefits from a decade of surveillance. J Antimicrob Chemother 56 Suppl. S2 (2005) ii3-ii21
16. Reinert R.R., Simic S., Al-Lahham A., Reinert S., Lemperle M., and Lütticken R. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. J Clin Microbiol 39 (2001) 1187-1189
17. Pletz M.W.R., Shergill A.P., McGee L., Beall B., Whitney C.G., and Klugman K.P. Active Bacterial Core Surveillance Team, Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 50 (2006) 1561-1563
18. Jones M.E., Staples A.M., Critchley I., et al. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study. Diagn Microbiol Infect Dis 37 (2000) 203-211
19. Reinert R.R., Reinert S., van der Linden M., Cil M.Y., Al-Lahham A., and Appelbaum P. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother 49 (2005) 2903-2913
20. Eller J., Ede A., Schaberg T., Niederman M.S., Mauch H., and Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 113 (1998) 1542-1548
21. Venezia R.A., Domaracki B.E., Evans A.M., Preston K.E., and Graffunder E.M. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother 48 (2001) 375-381
22. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y3118. Clin Infect Dis 32 Suppl. 1 (2001) S16-22
23. Woodford N., Ward M.E., Kaufmann M.E., et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother 54 (2004) 735-743
24. Pitout J.D.D., Nordmann P., Laupland K.B., and Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 56 (2005) 52-59
25. Livermore D.M., and Hawkey P.M. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 56 (2005) 451-454